European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

Innovations in Non-Muscle Invasive Bladder Cancer

Mon, 14 Mar 2016
Enlarge image

Full steam ahead on the fourth day of EAU16. Following the morning’s Plenary Session on ageing and the lower urinary tract, Thematic Session 13 addressed non-muscle invasive bladder cancer (NIMBC) through several hot-topic and state-of-the-art lectures.

Dr. Gianluca Giannarini (IT) spoke on evidence-based upper urinary tract (UUT) surveillance in patients with bladder cancer, or rather, the lack thereof.

“In terms of the evidence base, we only have retrospective, non-comparative, non-controlled cohort studies at our disposal,” he said. “There have been a few surveillance protocols for UUT, but these are diverse, non-validated and mainly stage-adapted.”

“We therefore have no high-grade recommendations on whom to monitor, how to monitor, how often of for how long patients should be monitored for upper tract urothelial carcinoma (UTUC).”

Giannarini concluded his Hot Topic Lecture with some directions for next steps: “The risk of upper tract urothelial carcinoma in bladder cancer patients is a lifelong constant, and high-grade recommendations as to schedule, intensity and duration of UUT surveillance cannot be made at present.”

“Risk-adapted UUT surveillance, that is to say intensive CT-urography for high-risk NMIBC, is not sufficient to prevent the chance of nephroureterectomy or disease progression. The use of genomics will help identify optimal candidates for UUT surveillance.”

Kidney-sparing treatment of UTUC

Dr. Sharokh Shariat (AT) followed with his state-of-the-art lecture on the merits of kidney-sparing surgery (KSS) over radical nephroureterectomy.

Showing some examples of removed kidneys with in some cases only small tumours, Shariat pointed out that “at the moment, one size fits all and there is a serious risk of over-treatment.” His lecture was based on three questions: Why should urologists consider KSS, if it is safe and equally as effective as radical surgery, and finally which patients should be considered for kidney-sparing surgery.

“The rationale for kidney-sparing surgery is clear, but I must disclose that data is currently weak. Ureteroscopy is useful for diagnosis, but there is a risk of delaying the definitive treatment.” Shariat emphasized that diagnostic URS increased the risk of intravesical recurrence, as published by Sung et al, Plos One 2015.

Shariat also recommended the use of a digital ureteroscope for the best results, and demonstrated a “push” technique with the Piranha. He impressed on urologists that it was also their responsibility to inform their patients on the dangers of smoking, seeing as it was associated with recurrence and mortality. The cessation of smoking for >10 years reduces the risk significantly.

Innovations in Non-Muscle Invasive Bladder Cancer

Share this article

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer